Novavax, Inc. (FRA:NVV1)

Germany · Delayed Price · Currency is EUR

7.75

-0.07 (-0.84%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Development of Recombinant Vaccines	682.16M	983.71M	1.98B	1.15B	475.60M
Development of Recombinant Vaccines Growth	-30.65%	-50.36%	72.89%	141.02%	2448.48%
Total	682.16M	983.71M	1.98B	1.15B	475.60M
Total Growth	-30.65%	-50.36%	72.89%	141.02%	2448.48%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Europe	93.27M	268.36M	-	-	-
Europe Growth	-65.24%	-	-	-	-
Rest of The World	31.92M	233.07M	-	-	-
Rest of The World Growth	-86.30%	-	-	-	-
North America	65.02M	29.96M	-	-	-
North America Growth	117.04%	-	-	-	-
Total	190.21M	531.39M	-	-	-
Total Growth	-64.20%	-	-	-	-

Source: S&P Global Market Intelligence.